GlassScriptPhysician profile
Trenton D Gray
NPI 1639692510
$40,313.09
in general payments reported to CMS, 2019-2025
25 companies · $6,518 in 2025
The $6,518 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $6,097 · 2023: $26K · 2024: $910 · 2025: $6,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $22K · Travel and Lodging: $4,243 · Food and Beverage: $3,593 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,700 · Consulting Fee: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $22,387.50 |
| Travel and Lodging | $4,243.40 |
| Food and Beverage | $3,592.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,700.00 |
| Consulting Fee | $907.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $30,951.57 | 2021-2023 | Krystexxa |
| Amgen INC. | $3,723.49 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Ani Pharmaceuticals, INC. | $2,085.21 | 2022-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $907.50 | 2025 | Rivfloza |
| Astrazeneca Pharmaceuticals LP | $514.01 | 2021-2024 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.10 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $260.20 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $213.50 | 2022-2024 | |
| Vifor Pharma, INC. | $198.99 | 2021-2024 | Veltassa |
| Lilly USA, LLC | $163.66 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $160.38 | 2021-2025 | Benlysta |
| Fresenius USA Marketing, INC. | $131.44 | 2021-2025 | Velphoro, Korsuva, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $130.71 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $114.37 | 2021-2024 | Givlaari |
| Ardelyx, INC. | $98.03 | 2024-2025 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $65.08 | 2022 | |
| Alexion Pharmaceuticals, INC. | $61.93 | 2022-2025 | Ultomiris |
| Xeris Pharmaceuticals, INC. | $46.88 | 2021-2023 | Keveyis |
| Calliditas Therapeutics US INC. | $44.71 | 2022-2023 | Tarpeyo |
| Veloxis Pharmaceuticals, INC. | $44.11 | 2023 | Envarsus |
| Chiesi USA, INC. | $35.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.96 | 2022 | |
| Aurinia Pharma U.S., INC. | $23.40 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trenton Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.